Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia

Immunotherapy has shown limited success in acute myeloid leukemia (AML), indicating an incomplete understanding of the underlying immunoregulatory mechanisms. Here we identify an immune evasion mechanism present in 60% of AML cases, wherein primitive AML cells aberrantly express the lymphoid surface protein SLAMF6 (signaling lymphocyte activation molecule family member 6). Knockout of SLAMF6 in AML cells enables T cell activation and highly efficient killing of leukemia cells in coculture systems, demonstrating that SLAMF6 protects AML cells from recognition and elimination by the immune system in a mode analogous to the programmed cell death protein-ligand (PDL1/PD1) axis. Targeting SLAMF6 with an antibody against the SLAMF6 dimerization site inhibits the SLAMF6-SLAMF6 interaction and induces T cell activation and killing of AML cells both in vitro and in humanized in vivo models. In conclusion, we show that aberrant expression of SLAMF6 is a common and targetable immune escape mechanism that could pave the way for immunotherapy in AML.

Authors

Institutions

Publication Details

Journal
Nature Cancer
Published
2025-10-03
DOI
https://doi.org/10.1038/s43018-025-01054-6
Citations
1
Primary Topic
Immune Cell Function and Interaction
Type
article
Field-Weighted Citation Impact
0.80
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia

Helena Ågerstam, Henrik Lilljebjörn, Axel Hyrenius‐Wittsten, Carl Sandén et al.
1 citations
Nature Cancer
Immune Cell Function and Interaction
0.80
article

Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia

Helena Ågerstam, Henrik Lilljebjörn, Axel Hyrenius‐Wittsten, Carl Sandén, Maria Rodriguez‐Zabala, Thoas Fioretos, Pablo Peña‐Martínez, Marianne Rissler, Sofia von Palffy, Noelia Puente‐Moncada, Gunnar Juliusson, Niklas Landberg, Hanna Thorsson, Shruti Daga, Christina Orsmark‐Pietras, Mats Ohlin, Vladimir Lazarević
article en
1 citations

Abstract

Immunotherapy has shown limited success in acute myeloid leukemia (AML), indicating an incomplete understanding of the underlying immunoregulatory mechanisms. Here we identify an immune evasion mechanism present in 60% of AML cases, wherein primitive AML cells aberrantly express the lymphoid surface protein SLAMF6 (signaling lymphocyte activation molecule family member 6). Knockout of SLAMF6 in AML cells enables T cell activation and highly efficient killing of leukemia cells in coculture systems, demonstrating that SLAMF6 protects AML cells from recognition and elimination by the immune system in a mode analogous to the programmed cell death protein-ligand (PDL1/PD1) axis. Targeting SLAMF6 with an antibody against the SLAMF6 dimerization site inhibits the SLAMF6-SLAMF6 interaction and induces T cell activation and killing of AML cells both in vitro and in humanized in vivo models. In conclusion, we show that aberrant expression of SLAMF6 is a common and targetable immune escape mechanism that could pave the way for immunotherapy in AML.

Nature CancerVol. 6(11)
Lund University (SE), Skåne University Hospital (SE)
Openalex Percentile: Top 23%
Immune Cell Function and Interaction
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.